This post was originally published on this site
A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said.
Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment.
